๊ธ๋ฃจ์ฝ์ฝ๋ฅดํฐ์ฝ์ด๋
๊ธ๋ฃจ์ฝ์ฝ๋ฅดํฐ์ฝ์ด๋๋ ํฌ์ ๋ฅ์ ๊ฑฐ์ ๋ชจ๋ ์ธํฌ ์ ํ๊ณผ ์์คํ ์ ๊น์ ์ํฅ์ ๋ฏธ์น๋ ๊ด๋ฒ์ํ ์คํ ๋ก์ด๋ ํธ๋ฅด๋ชฌ ๊ณ์ด์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก ๋ค์ ๋ค ๊ฐ์ง ๊ด๋ฒ์ํ ์ฉ๋ ๋ฒ์์ ์ ์์ฆ์ ์ฌ์ฉ๋ฉ๋๋ค: * **์๋ฆฌ์ ๋์ฒด ์๋ฒ:** ๋ถ์ ํผ์ง ๊ธฐ๋ฅ ์ ํ์ฆ(์: ์ ๋์จ๋ณ) ํ์์ฉ. * **ํญ์ผ์ฆ:** ์๋ ๋ฅด๊ธฐ ์ํ, ํธํก๊ธฐ ์งํ(์ฒ์), ํผ๋ถ ์งํ ๋ฐ ๊ณจ๊ด์ ์ผ ๊ด๋ฆฌ. * **๋ฉด์ญ ์ต์ :** ๋ฉด์ญ ๋งค๊ฐ์ฑ ์ฉํ์ฑ ๋นํ(IMHA), ํ์ํ ๊ฐ์์ฆ, ์ฒํฌ์ฐฝ, ์ ์ ์ฑ ํ๋ฐ์ฑ ๋ฃจํธ์ค์ ๊ฐ์ ์๊ฐ๋ฉด์ญ ์งํ์ฉ. * **ํญ์ข ์:** ํน์ ์ข ์(์: ๋ฆผํ์ข )์์ ์ธํฌ ๋ ์ฑ์ ๋ก ์ฌ์ฉ. **์์ ์์ :** ๊ณ ์์ด๋ ์ผ๋ฐ์ ์ผ๋ก ๊ฐ๋ณด๋ค ๋์ผํ ์์ ํจ๊ณผ๋ฅผ ์ป๊ธฐ ์ํด ๋ ๋์ ์ฉ๋์ด ํ์ํ์ง๋ง ๋ถ์์ฉ ๋ฐ์์ ๋ํ ์ ํญ๋ ฅ์ด ๋ ๊ฐํ ํธ์ ๋๋ค. ๋ฐ๋๋ก ๊ฐ๋ ๊ธ๋ฃจ์ฝ์ฝ๋ฅดํฐ์ฝ์ด๋์ ๋งค์ฐ ๋ฏผ๊ฐํ์ฌ ๋ง์ฑ์ ์ผ๋ก ์ฌ์ฉํ ๊ฒฝ์ฐ ์์ธ์ฑ ๋ถ์ ํผ์ง๊ธฐ๋ฅํญ์ง์ฆ(์ฟ ์ฑ ์ฆํ๊ตฐ)์ด ์ฝ๊ฒ ๋ฐ์ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Glucocorticoids exert their effects primarily by binding to cytosolic **glucocorticoid receptors (GR)**. The receptor-ligand complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) on DNA, altering gene transcription (transactivation and transrepression). * **Anti-inflammatory Pathway:** They induce the production of **lipocortin (annexin-1)**, which inhibits **phospholipase A2**. This blocks the release of **arachidonic acid** from cell membranes โ dramatically decreasing the synthesis of both **prostaglandins** and **leukotrienes**. * **Immune Suppression:** They inhibit macrophage function, decrease circulating T-lymphocytes, suppress inflammatory cytokines (IL-1, IL-6, TNF-alpha), and inhibit the complement cascade. * **Metabolic Effects:** Stimulate gluconeogenesis, mobilize amino acids, and redistribute adipose tissue, which can lead to insulin resistance.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Anti-inflammatory (Prednisolone equivalent) ยท 1.0-2.0 mg/kg ยท PO ยท q12h to q24h ยท Taper to lowest effective alternate-day dose ยท Cats require higher doses than dogs and should receive prednisolone, not prednisone.
- Immunosuppressive (Prednisolone equivalent) ยท 2.0-4.0 mg/kg ยท PO ยท q12h to q24h ยท Taper slowly over weeks to months ยท Monitor for signs of diabetes mellitus.
- Anti-inflammatory (Prednisolone equivalent) ยท 0.5-1.0 mg/kg ยท PO ยท q12h to q24h ยท Taper to lowest effective alternate-day dose ยท Doses are highly variable depending on the specific glucocorticoid used.
- Immunosuppressive (Prednisolone equivalent) ยท 2.0-4.0 mg/kg ยท PO ยท q24h (divided q12h initially) ยท Taper slowly over weeks to months ยท Monitor closely for severe adverse effects at these doses.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Systemic fungal infections (unless used for physiologic replacement)
- Intramuscular administration in patients with idiopathic thrombocytopenia
- Known hypersensitivity to the specific compound
- Chronic use of sustained-release injectables for systemic diseases
- Concurrent use with NSAIDs (relative contraindication due to severe GI ulcer risk)
- Pregnant animals
- Renal disease (systemic use)
- Diabetes mellitus (systemic use)
- Systemic fungal infections
- Corneal ulcers
- Concurrent use of NSAIDs
- Uncontrolled diabetes mellitus
- Late pregnancy (may induce abortion or parturition)
์ด์๋ฐ์
- Polyuria (PU), polydipsia (PD), and polyphagia (PP)
- Weight gain and fat redistribution
- Panting (especially in dogs)
- Dull, dry haircoat and alopecia
- Vomiting and diarrhea
- Gastrointestinal ulceration
- Elevated liver enzymes (ALP > ALT) and vacuolar hepatopathy (dogs)
- Pancreatitis
- Insulin resistance leading to or worsening diabetes mellitus
- Muscle wasting and weakness
- Behavioral changes (depression, lethargy, viciousness)
- Iatrogenic hyperadrenocorticism (Cushing's syndrome) with chronic use
- Laminitis (horses)
- Hypothalamic-pituitary axis (HPA) suppression
- Adrenal atrophy
์ฝ๋ฌผ ์ํธ์์ฉ
- Amphotericin B ยท May cause hypokalemia when administered concomitantly
- Anticholinesterase agents (e.g., pyridostigmine) ยท May lead to profound muscle weakness in myasthenia gravis patients; discontinue 24h prior if possible
- Aspirin (salicylates) ยท Glucocorticoids may reduce salicylate blood levels; increased risk of GI ulceration
- Cyclophosphamide ยท Glucocorticoids may inhibit hepatic metabolism of cyclophosphamide
- Cyclosporine ยท May mutually inhibit hepatic metabolism, increasing blood levels of both drugs
- Digoxin ยท Increased risk for arrhythmias secondary to glucocorticoid-induced hypokalemia
- Diuretics (potassium-depleting, e.g., furosemide) ยท May cause additive hypokalemia
- Ephedrine ยท May increase glucocorticoid metabolism
- Estrogens ยท May potentiate the effects of hydrocortisone and possibly other glucocorticoids
- Insulin ยท Insulin requirements may increase due to glucocorticoid-induced insulin resistance ยท moderate
- Ketoconazole ยท May decrease glucocorticoid metabolism
- Mitotane ยท May alter steroid metabolism; higher steroid doses may be necessary to treat mitotane-induced adrenal insufficiency
๋ชจ๋ํฐ๋ง
- Weight, appetite, and signs of edema
- Serum and/or urine electrolytes (potassium, calcium, sodium)
- Total plasma proteins and albumin
- Blood glucose
- Liver enzymes (ALP, ALT, GGT)
- Growth and development in young animals
- ACTH stimulation test (if assessing adrenal recovery or iatrogenic Cushing's)
- Clinical signs of hyperadrenocorticism
- Blood glucose (especially in diabetics)
- Electrolytes (potassium)
- Thyroid panel (T3/T4 may decrease)
- Clinical signs of PU/PD and weight gain
- Blood glucose (due to diabetes mellitus risk)
- ACTH stimulation test (to monitor HPA axis suppression)
- Water intake and urine output
๊ณผ์ฉ๋
Short-term massive overdoses are unlikely to cause acute harmful effects, though one case of acute CNS effects in a dog has been reported (treat supportively). Chronic overdosage leads to serious adverse effects manifesting as iatrogenic hyperadrenocorticism (Cushing's syndrome).
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.